Vital Signs: Healthcare Sector Outlook: September 2026
Healthcare markets reopened meaningfully in H1 2026, but selectivity persisted as M&A, clinical catalysts and China-origin BD drove momentum while rates and policy remain key go-forward risks
Healthcare Market Momentum, Policy Shifts & Strategic Considerations
The latest Vital Signs report from DNB Carnegie Back Bay examines the continued reopening of healthcare markets, and the factors that will determine whether that momentum will carry into 2027.
Key takeaways include:
Healthcare markets gained momentum: The XBI rose ~30% in H1 2026, outperforming the S&P 500 by ~21%, as strong clinical catalysts and M&A brought capital back into the sector
Dealmaking accelerated: Healthcare M&A reached ~$191B across 86 transactions in H1, while China-origin innovation continued to reshape licensing, with Chinese biotechs behind the four largest licensing deals
Financing conditions improved—but remain selective: 66 healthcare IPOs raised ~$11.2B, follow-ons reached ~$26.9B, and venture funding climbed to a three-year high of $17.7B, with capital concentrated around differentiated, catalyst-rich companies
Policy and macro risks are increasingly shaping strategy: Interest rates, Medicare negotiation and MFN pricing, tariffs, FDA execution, R&D funding and the midterms are becoming important considerations for financing, BD and M&A planning.
The takeaway? The healthcare markets are open, but not broad. Companies with differentiated data, strategic scarcity, capital runway and policy resilience remain best positioned as the sector looks toward 2027.
About DNB Carnegie Back Bay
The DNB Carnegie Back Bay Healthcare Partnership provides essential strategic and financial support to healthcare companies. We have a unique position bridging the Nordic and U.S. markets. Together, we provide a 360-degree understanding of healthcare corporate development, from chemistry to commercialization and raising capital to M&A as companies move through their lifecycle.
DNB, headquartered in Oslo, Norway, and Back Bay Life Science Advisors, headquartered in Boston, Massachusetts, are recognized leaders in banking and global life science development. Together, DNB Carnegie and Back Bay Life Science Advisors offer unique support to companies along the full continuum of life science and healthcare development.
Learn about the partnership and read our disclosures: www.bblsa.com/dnb-carnegie-back-bay-partnership